Recombinant Human Serum Albumin Market By Product Type (Rice-Derived rHSA, Yeast-Derived rHSA, Other rHSA); By Application (Pharmaceutical and Vaccine Formulation, Cell-Culture and Bioprocessing, Cell and Gene Therapy, Diagnostic Reagents, Therapeutic Albumin Injection); By End User (Biopharmaceutical and Vaccine Manufacturers, Cell and Gene Therapy Companies, Diagnostic Manufacturers, CDMOs, Research Institutions, Hospitals); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

Recombinant Human Serum Albumin Market: Qualified Bioprocess Demand and China’s Therapeutic Approval Create Two Commercial Pathways

The Global Recombinant Human Serum Albumin Market was valued at USD 113.7 million in 2025 and is projected to reach USD 206.3 million by 2032, growing at a CAGR of 8.9%, according to Strategic Market Research.

 

Recombinant human serum albumin, or rHSA, has achieved significant clinical and commercial progress, led by pioneering rice-derived formulations approved in China and advancing through Phase III clinical development in the United States. Produced without dependence on donated human plasma, rHSA provides a chemically defined and pathogen-free alternative to traditional plasma-derived human albumin. Its improving regulatory position is widening opportunities across therapeutic administration, vaccine formulation, biologic manufacturing, cell and gene therapy production, diagnostics and cell-culture applications.

 

Marketed Vaccines Demonstrate Long-Term Product Integration

Commercial vaccines provide direct evidence that rHSA can remain embedded in regulated products for many years. Sartorius reports that Recombumin has been used in Merck’s M-M-R II vaccine since 2006 and is also incorporated in ProQuad. More than 200 million M-M-R II doses containing Recombumin had reportedly been administered by 2026. This commercial exposure represents almost two decades of product integration and demonstrates the durability of supplier relationships once rHSA is qualified in a licensed vaccine.

The FDA label for Merck’s ERVEBO Ebola vaccine provides a more precise consumption reference. Each 1 mL dose contains 2.5 mg of rice-derived rHSA. Gavi maintains a target Ebola vaccine stockpile of 500,000 doses, equivalent to only 1.25 kilograms of rHSA based on the labeled formulation. The 145,690 doses shipped between 2021 and 2023 were equal to approximately 29.1% of the current stockpile target and represented around 0.364 kilograms of rHSA.

These figures show why downstream dose volume cannot be converted directly into rHSA revenue. The material can be essential to a licensed formulation while representing very little physical mass. Supplier value is created by regulatory acceptance, purity, consistency, documentation, batch reliability and the difficulty of changing an incorporated ingredient.

Vaccine demand can also be uneven. CDC reported that 208,390 Ebola stockpile doses were scheduled to expire in 2024, while only 5% of shipments during 2021–2023 were used for outbreak response. Preventive vaccination accounted for approximately 95% of distributed doses during the period. Stockpile replacement therefore creates recurring procurement, but annual ordering remains influenced by outbreak activity, preventive campaigns, expiry and inventory policy.

 

Advanced Therapies Expand the Addressable Customer Base

Cell and gene therapy development is broadening the potential customer universe for ancillary- and formulation-grade rHSA. An analyst count of the FDA’s July 1, 2026 list identified 50 licensed cellular and gene therapy products in the United States. Not every product uses rHSA, but the total indicates a growing pool of commercial programs that may require qualified cell-culture, formulation or cryopreservation materials.

The European Medicines Agency reported that 51 advanced therapy medicinal product marketing applications had been submitted since 2009. By June 2026, the agency had issued 34 positive opinions corresponding to 33 ATMPs. Positive opinions therefore covered approximately 64.7% of the number of submitted applications, although the figures span different development periods and should not be interpreted as an approval rate. EMA also recorded hundreds of scientific-advice procedures and classification requests, showing continued development activity beyond products that have already reached authorization.

Commercial opportunity in advanced therapies begins before approval. Material demand starts during research and process development, increases during clinical manufacturing and becomes recurring when a therapy reaches commercial production. Programs that are discontinued, delayed or manufactured for small patient populations generate less revenue, so approved-product counts should be treated as customer-universe indicators rather than direct measures of rHSA consumption.

Advanced therapies also raise the cost of supply disruption. Individual manufacturing batches can carry substantial economic value even when production volume is low. Buyers therefore place strong emphasis on traceability, lot consistency, change control, regulatory packages and supply assurance. These requirements strengthen the position of qualified suppliers after they enter a validated manufacturing process.

 

Regulated Diagnostics Turn Animal-Origin Substitution into Commercial Demand

The diagnostic segment gained an important regulatory precedent in May 2026 when the FDA approved a QIAGEN premarket approval supplement allowing bovine serum albumin to be replaced with rHSA in PCR master-mix tubes used with the therascreen FGFR RGQ RT-PCR Kit. The approval moves animal-origin substitution from a development concept into a validated material change within a regulated commercial diagnostic.

Diagnostic demand can become recurring because approved kits generate repeat reagent production. Conversion still requires evidence that the replacement material maintains analytical performance, stability and manufacturing consistency. Suppliers able to provide reproducible lots, documentation and change-control support are therefore better positioned than vendors competing only on research-grade price.

Competition widened in February 2026 when Proliant Health and Biologicals launched AlbuFree DX using Dyadic’s production platform. Dyadic disclosed that it would receive a share of profits from commercial sales, introducing a partnership-based revenue structure rather than a conventional fixed-price supply arrangement. The launch adds another supplier for diagnostic and life-science applications and may increase pricing pressure in research and diagnostic grades. Injectable excipients and materials already qualified in licensed biological products remain more protected by regulatory switching costs.

 

China Creates a Direct Therapeutic Revenue Pathway

China is the main market testing prescription-driven rHSA demand. In July 2025, Chinese authorities approved Healthgen’s rice-derived recombinant human albumin injection for patients with cirrhosis-related hypoalbuminemia and serum albumin levels at or below 30 g/L. The 10 g/50 mL product moves rHSA beyond its traditional role as a manufacturing input and into direct hospital administration.

A multicenter randomized trial conducted across 22 Chinese centers treated 220 patients between March 2021 and June 2022. Of these, 175 patients, or approximately 79.5% of the trial population, received rice-derived rHSA, while 45 patients, or 20.5%, received plasma-derived human albumin. The full-analysis population included 216 patients, representing approximately 98.2% of all enrolled participants.

The primary albumin threshold was achieved by 76.0% of evaluable rHSA recipients and 75.6% of plasma-albumin recipients. The difference between the two groups was only 0.4 percentage points, supporting non-inferiority in the trial setting and providing a commercial basis for positioning rHSA as an alternative to established plasma-derived albumin.

Treatment was administered once daily at 10 g or 20 g until the albumin target was reached or for a maximum of two weeks. The higher dose was twice the standard 10 g level, and a full two-week course could create materially greater albumin consumption than vaccine excipient applications, where usage is measured in milligrams per final dose. This dosing pattern gives the therapeutic segment a stronger potential contribution to physical market volume.

Healthgen has completed a commercial-scale rHSA bulk and formulation line with annual nameplate capacity of approximately 10 tons and built a distribution network across more than 30 Chinese provinces and municipalities. The installed capacity is equivalent to up to one million 10 g treatment units before manufacturing losses, product allocation and utilization are considered. This infrastructure shows national commercialization intent, but capacity will convert into revenue only as hospitals list the product, physicians prescribe it and payment access improves.

Reimbursement is the main conversion point. China’s existing reimbursement catalogue includes plasma-derived human albumin under restricted clinical conditions, creating a possible precedent for the approved rHSA indication. Healthgen submitted its product for national coverage, although wider access would likely involve price negotiation, provincial implementation and hospital pharmacy committee approval. Reimbursement could increase treatment volume while reducing per-vial revenue and supplier margins.

Plasma-derived albumin remains the established comparator with decades of physician familiarity and existing procurement channels. The Chinese rHSA product must therefore compete on clinical confidence, supply reliability, safety perception, formulary access and relative pricing rather than approval alone.

 

Premium Value Is Concentrated in Regulated Grades

Pricing power differs sharply across rHSA grades. Research-use material is more exposed to supplier comparison and small-volume price competition. Diagnostic-grade products retain value through reproducibility and documentation but are attracting new entrants. Cell-culture and ancillary materials command stronger positions when they are incorporated into regulated manufacturing. Injectable excipient-grade rHSA carries the highest switching burden because the material becomes part of a licensed formulation.

InVitria’s displayed Exbumin pricing provides a public reference for premium small-pack material. A 10 g pack was listed at approximately USD 950, equal to USD 95 per gram, while a 100 g pack was listed at USD 8,170, or USD 81.70 per gram. The larger pack reduced the displayed price by USD 13.30 per gram and represented a quantity discount of approximately 14%.

Compendial positioning also supports premium procurement. The USP rAlbumin Human monograph covers recombinant albumin produced using yeast and supplied as sterile 10% or 20% solutions. The 20% formulation contains twice the albumin concentration of the 10% formulation, allowing manufacturers to address different formulation and administration requirements. A recognized monograph gives pharmaceutical buyers a clearer quality framework for testing, documentation and regulatory filing, strengthening demand for suppliers able to meet compendial and cGMP requirements.

 

Competition Is Shifting Toward Regulatory Position and Market Access

Sartorius and Albumedix hold a strong position in cGMP excipient and ancillary applications, supported by long-standing vaccine use and Sartorius’s wider bioprocess commercial network. Albumedix’s expected revenue of £33 million in 2022 provides one of the few disclosed company-level revenue indicators within the niche, while the £415 million acquisition price demonstrates the premium attached to qualified technology, regulatory capability and established customer integration.

Ventria and InVitria combine rice-derived production with commercial vaccine precedent, visible catalog supply and an established US intellectual-property position. Healthgen is pursuing both manufacturing-input sales and direct therapeutic commercialization in China, supported by its 10-ton annual capacity but exposed to reimbursement, adoption and international access risks.

Proliant and Dyadic are increasing competition in diagnostic and life-science grades through AlbuFree DX. QIAGEN represents a strategically important downstream adopter because its FDA-approved switch from bovine to recombinant albumin provides direct evidence of regulated customer conversion. Merck’s vaccines demonstrate how qualification in a licensed product can create long-duration supplier demand without rHSA being separately visible to the final payer.

Intellectual property remains a material barrier in plant-derived production. The US International Trade Commission issued a limited exclusion order covering specified infringing plant-derived rHSA products associated with Healthgen, and the US Court of Appeals for the Federal Circuit affirmed the infringement finding in February 2025. The ruling strengthens suppliers with domestic production, valid licensing or non-infringing technologies and may influence future partnerships, platform selection and regional commercialization strategies.

 

Regional Opportunity Follows Different Demand Models

The United States offers the strongest recent evidence of regulated diagnostic substitution and a sizeable advanced-therapy manufacturing base, represented by 50 FDA-listed cellular and gene therapy products in July 2026. Its commercial opportunity remains concentrated in qualified ingredients and ancillary materials rather than direct rHSA treatment.

Europe provides a substantial ATMP development and authorization base, including 33 products corresponding to positive EMA opinions by June 2026. This supports demand for cell-culture, cryopreservation and formulation inputs. The United Kingdom retains strategic importance through Albumedix’s specialized manufacturing and development capabilities within Sartorius.

China is the most important region for direct pharmaceutical commercialization. Approval of the 10 g/50 mL therapeutic product, annual nameplate capacity of 10 tons and distribution preparation across more than 30 provinces and municipalities create the foundation for a patient-led market. Reimbursement, hospital listing and physician adoption will determine the pace at which this capacity converts into commercial revenue.

Global vaccine procurement provides a separate demand stream. The 500,000-dose ERVEBO stockpile target offers confirmed downstream use and procurement-backed purchasing, but the corresponding rHSA requirement of approximately 1.25 kilograms demonstrates that this pathway is strategically valuable while remaining low in physical volume.

 

Recombinant Human Serum Albumin Market Report Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 113.7 Million
Revenue Forecast in 2032	USD 206.3 Million
Overall Growth Rate	CAGR of 8.9% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Million, CAGR (2026 – 2032)
Segmentation	By Product Type, By Application, By End User, By Geography
By Product Type	Rice-Derived rHSA, Yeast-Derived rHSA, Other rHSA
By Application	Pharmaceutical and Vaccine Formulation, Cell-Culture and Bioprocessing, Cell and Gene Therapy, Diagnostic Reagents, Therapeutic Albumin Injection
By End User	Biopharmaceutical and Vaccine Manufacturers, Cell and Gene Therapy Companies, Diagnostic Manufacturers, CDMOs, Research Institutions, Hospitals
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East and Africa
Country Scope	U.S., Canada, UK, Germany, France, Italy, China, Japan, South Korea, India, Brazil, Mexico, Saudi Arabia, UAE, South Africa
Market Drivers	Increasing demand for recombinant alternatives to plasma-derived albumin, expansion of biopharmaceutical manufacturing and cell therapy pipelines, growing adoption of serum-free and animal-component-free production systems
Customization Option	Available upon request